Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | DBH | P09172 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108477 | 0.80 | TAAR1 (0.50) | DAOMAOATAAR1HPGD | |
| SCHEMBL11385118 | 0.79 | DAO (0.49) | DAOLMNAIDO1DBHMAOA | |
| SCHEMBL28399049 | 0.79 | HRH3 (0.52) | IDO1MAOATAAR1ALDH1A1 | |
| SCHEMBL27533766 | 0.79 | CYP3A4 (0.52) | LMNALOXL2MAOAALDH1A1GAA | |
| SCHEMBL1856737 | 0.79 | TP53 (0.41) | MAOATAAR1ALDH1A1 | |
| SCHEMBL23528212 | 0.79 | DAO (0.44) | DAOIDO1MAOATAAR1C3AR1 | |
| SCHEMBL20117722 | 0.79 | DAO (0.53) | DAOIDO1DBHTAAR1P2RX7 | |
| SCHEMBL28229595 | 0.79 | TAAR1 (0.41) | DAOIDO1MAOATAAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27287864 | 0.78 | TAAR1 (0.48) | DAOMAOATAAR1MAPTHPGD | |
| SCHEMBL27647887 | 0.78 | TAAR1 (0.43) | LMNAIDO1TAAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939291-B2 | GRP94 selective inhibitors and uses thereof | UNIVERSITY OF KANSAS (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS | 2022-01-27 | — | — | US | disclosed |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS | 2022-01-27 | — | — | US | disclosed |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10975030-B2 | Grp94 selective inhibitors and uses thereof | UNIVERSITY OF KANSAS (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975030-B2 | Grp94 selective inhibitors and uses thereof | UNIVERSITY OF KANSAS (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200071271-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2020-03-05 | — | — | US | disclosed |
| US-20200071271-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2020-03-05 | — | — | US | disclosed |
| WO-2018081814-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS (US) | 2018-05-03 | — | — | WO | disclosed |
| CN-100491349-C | Antiviral agent | SHIONOGI & CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| EP-1142872-B1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7098201-B2 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| CN-1558898-A | Antiviral agent | ��Ұ����ҩ��ʽ���� | 2004-12-29 | — | — | CN | disclosed |
| CN-1178913-C | Aromatic heterocycle compounds having HIV integrase inhibiting activities | ��Ұ����ҩ��ʽ���� | 2004-12-08 | — | — | CN | disclosed |
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | FUJISHITA TOSHIO (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6645956-B1 | 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment | SHIONOGI & CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6620841-B1 | Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) | SHIONOGI & CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| CN-1335834-A | Aromatic heterocyclic compounds having HIV integrase inhibitory activity | SHIONOGI & CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1142872-A1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | RCOR1, BCOR, CYP8B1 | DAO 661/4885LMNA 659/4885IDO1 34/4885 |
| US-20200071271-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | GRPR, HSP90B1, HSPE1 | DAO 4189/4885LMNA 4283/4885IDO1 4602/4885 |
| US-11939291-B2 | GRP94 selective inhibitors and uses thereof | GRPR, HSP90B1, HSPE1 | DAO 4189/4885LMNA 4283/4885IDO1 4602/4885 |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | GRPR, HSP90B1, HSPE1 | DAO 4189/4885LMNA 4283/4885IDO1 4602/4885 |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | ATM, CHEK2, CHEK1 | DAO 4122/4885LMNA 1150/4885IDO1 3764/4885 |
| US-10975030-B2 | Grp94 selective inhibitors and uses thereof | GRPR, HSP90B1, HSPE1 | DAO 4189/4885LMNA 4283/4885IDO1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.